All News

The vaginal inserts can reduce symptoms such as hot flashes and mood swings.

Officials with the FDA have approved fremanezumab-vfrm (Ajovy, Teva) for the preventive treatment of migraine in adults.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

Top news of the day from across the health care landscape.

Study identifies receptor as potential target for reversing liver damage and preventing progression to cancer.

Top news of the day from across the health care landscape.

Officials with the FDA have approved fremanezumab-vfrm (Ajovy, Teva) for the preventive treatment of migraine in adults.

Growth in midlife mortality includes conditions such as heart disease, liver cancer, pulmonary disease, obesity, and neurologic disorders.

Officials with the FDA have approved fremanezumab-vfrm (Ajovy, Teva) for the preventive treatment of migraine in adults.

A second unexpected impurity was shown in 3 lots of Torrent Pharmaceuticals’ recalled drug products during an ongoing FDA investigation.

As growing levels of antibiotic resistance continues to concern health care professionals, the results of a recent study suggest that giving daily probiotic supplements to children can reduce their likelihood of requiring antibiotics.

Pamrevlumab is advancing towards phase 3 clinical development for idiopathic pulmonary fibrosis early next year.

Some researchers propose that vasomotor symptoms may signal physiologic processes that might be associated with other related systemic health diagnoses.

Presenters at the International Pharmaceutical Federation (FIP) World Congress in Glasgow, Scotland identified the current landscape of Hepatitis C, how pharmacists can position themselves to aid in point of care testing, and ways to better educate patients and providers.

Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with hairy cell leukemia.

The FDA has accepted for review Regeneron Pharmaceuticals’ supplemental Biologics License Application (sBLA) of aflibercept (EYLEA Injection) to treat diabetic retinopathy.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Officials with the FDA have approved AstraZeneca’s moxetumomab pasudotox-tdfk (Lumoxiti) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least 2 prior systemic therapies.

A second unexpected impurity was shown in 3 lots of Torrent Pharmaceuticals’ recalled drug products during an ongoing FDA investigation.

The FDA has accepted for review Regeneron Pharmaceuticals’ supplemental Biologics License Application of aflibercept (EYLEA Injection) to treat diabetic retinopathy.

A recent survey evaluated the baseline knowledge of licensed pharmacists with regard to common pet toxins.

Tocilizumab’s newest formulation offers an additional administration option for children diagnosed systemic juvenile idiopathic arthritis, a rare and debilitating disease.

Azathioprine, a drug used to treat a variety of conditions, may contribute to skin cancer development.

More than 65% of patients with Kaposi’s sarcoma in a small cohort had partial or complete remission when treated with immune checkpoint inhibitors.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

B cells activate T cells in the blood to cause inflammation and brain lesions in patients with multiple sclerosis.

One in 5 test results showed potentially dangerous concurrent use of opioids and benzodiazepines in 2017.